Sodium Hyaluronate plus Niacinamide

The first VISCO-BOOSTER

INNORYOS is the first intra-articular injection made of hyaluronic acid and niacinamide.

This two key ingredients enable a dual effect to counterbalance the deleterious effect of osteoarthritis on synovial fluid and cartilage.

Packaging

The Dual Effect

This innovative formulation has been designed to offer unique antioxidant properties for a reinforced gel against free radical degradation compared to linear and cross linked HA.

The dual effect

INNORYOS mode of action

The first intra-articular injection made of Hyaluronic Acid and Niacinamide

INNORYOS treatment enables to restore the viscosity and elasticity of endogenous synovial fluid to reestablish homeostasis of the joint.

With its high resistance to oxidative degradation, the viscoelastic properties of the gel are preserved offering outstanding lubrication properties and better cartilage protection, to maximize the treatment outcomes.

Preservation of HA integrity

  • Anti-oxidant power
  • Limits inflammation

Improves cartilage conditions

  • Preservation of chondrocytes viability
  • Synthesis of collagen type II

Provides better mobility

  • Acts on pain mediators
  • Improves joint function

INNORYOS features

INNORYOS is a new generation treatment that acts on all the aspects of osteoarthritis to improve the joint function of OA patients.

Features
Syringe

References

  1. Hummer, C.D., Angst, F., Ngai, W. et al. High molecular weight Intraarticular hyaluronic acid for the treatment of knee osteoarthritis: a network meta-analysis. BMC Musculoskelet Disord 21, 702 (2020). https://doi.org/10.1186/s12891-020-03729-w
  2. Ogata S, Takeuchi M, Teradaira S, Yamamoto N. Iwata K. Okumura K, Taguchi H. Radical scavenging activities of niacin- related compounds. Biosci Biotechnol Biochem. 2002 Mar;66(3): 641-5. doi: 10.1271/bbb.66.641. PMID: 12005062
  3. Jonas WB, Rapoza CP, Blair WF. The effect of niacinamide on osteoarthritis: a pilot study. Inflamm Res. 1996 Jul:45(7):330. 4. doi: 10.1007/BF02252945. PMID: 8841834
  4. Atlantic Bone Screen, assigned by ALBOMED GmbH. In- vitro evaluation of the anti-hypertrophic effect of 1 product on rat chondrocytes.2019

Would you like to have more information?

Then simply get in touch with us. Our product management team will support you with detailed information about our innovation INNORYOS.